Form 8-K - Current report:
SEC Accession No. 0001193125-22-295491
Filing Date
2022-11-30
Accepted
2022-11-30 17:10:55
Documents
18
Period of Report
2022-11-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d424988d8k.htm   iXBRL 8-K 29713
2 EX-1.1 d424988dex11.htm EX-1.1 193679
3 EX-5.1 d424988dex51.htm EX-5.1 8396
4 EX-99.1 d424988dex991.htm EX-99.1 8331
5 EX-99.2 d424988dex992.htm EX-99.2 8969
9 GRAPHIC g424988g1130110152670.jpg GRAPHIC 1502
10 GRAPHIC g424988g1130111103857.jpg GRAPHIC 9109
  Complete submission text file 0001193125-22-295491.txt   449616

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20221128.xsd EX-101.SCH 2838
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20221128_lab.xml EX-101.LAB 17235
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20221128_pre.xml EX-101.PRE 10804
12 EXTRACTED XBRL INSTANCE DOCUMENT d424988d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 221436257
SIC: 2834 Pharmaceutical Preparations